<DOC>
	<DOCNO>NCT03038516</DOCNO>
	<brief_summary>To test hypothesis vitamin D treatment 12 week palliative cancer patient decrease opioid consumption , fatigue infectious burden increase quality life .</brief_summary>
	<brief_title>'Palliative-D ' Vitamin D Palliative Cancer Patients</brief_title>
	<detailed_description>PROTOCOL IDENTITY AND OBJECTIVES : EudraCT Number 2017-000268-14 Protocol Title : Vitamin D supplementation palliative cancer patient - A double blind , randomise control trial . Acronym : `` Palliative-D '' Trial Objectives : To test hypothesis vitamin D treatment 12 week palliative cancer patient decrease opioid consumption , fatigue infectious burden increase quality life . INVESTIGATIONAL MEDICINAL PRODUCTS ( IMP ) : Test ProductDetremin , MA holder Renapharma ; Pharmaceutical Form : Oil Route Administration : Oral route METHODOLOGY Trial Design : Double-blind , parallel randomise placebo control trial Dose/Duration 4000 IU/day 12 week Primary Endpoint : The decline opioid-consumption 12 week vitamin D group compare placebo group , base 3 measurement 4 week interval . Secondary end Points : 1 . Decline antibiotic consumption 2 . Improvement quality life 3 . Improvement fatigue 4 . Vitamin D level serum 12 week 5 . Association opioid dose genetic polymorphism gene involve effect metabolism vitamin D body . Efficacy Parameters : Opioid dose , translate fentanyl per hour measure baseline week 4,8 12 . Antibiotic consumption express % day antibiotic last 4 week measure baseline week 4 , 8 12 . Quality Life measure EORTC-QLQ-C15-PAL baseline 12 week . Fatigue measure EORTC-QLQ-C15-PAL baseline 12 week . 25-hydroxyvitamin D level blood baseline 12 week . ESAS ( Edmonton Symptom Assessment Scale ) measure baseline week 4 , 8 12 . Safety Parameters : S-calcium control subject baseline , week 4 , 8 12 U-calcium select case Power : The least clinically meaningful effect estimate 20 % decline opioid dose compare placebo . To obtain result 80 % power number patient estimate 127 arm i.e . 254 patient total . This include drop-out 25 % per group . Statistical Analyse plan : The primary endpoint analyse use linear regression , use bias correct accelerate bootstrap confidence interval , control baseline measure opioid dose ( similar ANCOVA ) . Adjustment background variables - vitamin D-level baseline , gender age - make secondary analysis gain efficiency . The continuous secondary endpoint analyse use method primary endpoint . POPULATION OF TRIAL SUBJECTS Number Subjects : 254 ( 127 vitamin D 127 placebo ) Description Trial Subjects : Palliative Cancer Patients ( cancer form ) life expectancy 3 month . TRIAL TIMETABLE First Subject In Aug 2017 Last Subject In Sept 2019 ( 25 month include participant ) Last Subject Out Dec 2019 End intervention Dec 2019 End follow Dec2019 End Trial : Dec 2020</detailed_description>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . Patients admit ASIH Stockholm Södra Stockholms Sjukhem . 2 . Incurable cancer patient type cancer . They could ongoing oncological treatment palliative intention . No patient ongoing oncological treatment curative intend treat include . 3 . The life expectancy least 3 month accord clinical assessment study physician screen visit . 4 . The patient cognitive failure , able comprehend oral write information study . 5 . 25 OHD &lt; 50 nmol/L . 6 . Men woman age ≥18 7 . Signed 'informed consent ' 1 . Ongoing vitamin D calcium supplementation time inclusion . 2 . Serum level 25OH vitamin D3 &lt; 50 nmol/L 3 . Known sarkoidosis 4 . Treatment tiazides 5 . Primary hyperparathyroidism 6 . Hypercalcaemia ( verified laboratory result young 2 month ) 7 . Plans leave Stockholm county within 12 week inclusion 8 . History kidney stone 9 . Taking part another clinical study involve drug 10 . Hypersensitivity cholecalciferol and/or excipients 11 . Other criterion could jeopardize study intention judge investigator 12 . Not able perform EORTCQLQC15PAL ESAS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>